Trevi Therapeutics, Inc. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
Trevi Therapeutics, Inc. (TRVI) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $0 as of 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2026-03-17
- 2025-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $0.00.
- 2025-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $0.00.
- 2025-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $0.00.
- 2024-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $157.00K.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-17 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-13 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 |
| 2024-12-31 | $157.00K 10-K · filed 2026-03-17 |
| 2024-09-30 | $169.00K 10-Q · filed 2024-11-06 |
| 2024-06-30 | $181.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $194.00K 10-Q · filed 2024-05-07 |
| 2023-12-31 | $206.00K 10-K · filed 2025-03-18 |
| 2023-09-30 | $218.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $230.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $242.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |